fmx-8
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01873534)
Timeline
Indications
Mechanism of action
- Bone morphogenetic protein 1Supplementation
BMP1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- fmx-8
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02228655 | Early Phase 1 (Phase 1) | Oct 1, 2014 | FerruMax Pharmaceuticals, Inc., Harvard University |
| NCT01873534 | Phase 2 | Jun 1, 2013 | Davita Clinical Research, FerruMax Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FerruMax Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2013 |
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2013 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1